BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11592771)

  • 21. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
    Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
    Allen NE; Key TJ; Appleby PN; Travis RC; Roddam AW; Rinaldi S; Egevad L; Rohrmann S; Linseisen J; Pischon T; Boeing H; Johnsen NF; Tjønneland A; Grønbaek H; Overvad K; Kiemeney L; Bueno-de-Mesquita HB; Bingham S; Khaw KT; Tumino R; Berrino F; Mattiello A; Sacerdote C; Palli D; Quirós JR; Ardanaz E; Navarro C; Larrañaga N; Gonzalez C; Sanchez MJ; Trichopoulou A; Travezea C; Trichopoulos D; Jenab M; Ferrari P; Riboli E; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1121-7. PubMed ID: 17548673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
    Finne P; Auvinen A; Koistinen H; Zhang WM; Määttänen L; Rannikko S; Tammela T; Seppälä M; Hakama M; Stenman UH
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China.
    London SJ; Yuan JM; Travlos GS; Gao YT; Wilson RE; Ross RK; Yu MC
    J Natl Cancer Inst; 2002 May; 94(10):749-54. PubMed ID: 12011225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.
    Chan JM; Stampfer MJ; Giovannucci E; Gann PH; Ma J; Wilkinson P; Hennekens CH; Pollak M
    Science; 1998 Jan; 279(5350):563-6. PubMed ID: 9438850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-like growth factors and breast cancer risk in Chinese women.
    Yu H; Jin F; Shu XO; Li BD; Dai Q; Cheng JR; Berkel HJ; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):705-12. PubMed ID: 12163322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J; Diamandi A; Mistry J; Scorilas A
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature.
    Sugumar A; Liu YC; Xia Q; Koh YS; Matsuo K
    Int J Cancer; 2004 Aug; 111(2):293-7. PubMed ID: 15197785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
    Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
    Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women.
    Probst-Hensch NM; Wang H; Goh VH; Seow A; Lee HP; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):739-46. PubMed ID: 12917205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men.
    Ma J; Giovannucci E; Pollak M; Chan JM; Gaziano JM; Willett W; Stampfer MJ
    J Natl Cancer Inst; 2001 Sep; 93(17):1330-6. PubMed ID: 11535708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study.
    Mucci LA; Stark JR; Pollak MN; Li H; Kurth T; Stampfer MJ; Ma J
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):484-91. PubMed ID: 20142246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer.
    Latif Z; McMillan DC; Wallace AM; Sattar N; Mir K; Jones G; Underwood MA
    BJU Int; 2002 Mar; 89(4):396-9. PubMed ID: 11872031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
    Chen C; Freeman R; Voigt LF; Fitzpatrick A; Plymate SR; Weiss NS
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2461-6. PubMed ID: 17164371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
    Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.
    Palmqvist R; Hallmans G; Rinaldi S; Biessy C; Stenling R; Riboli E; Kaaks R
    Gut; 2002 May; 50(5):642-6. PubMed ID: 11950809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.